Why is McKesson falling?

Editorial team Published on

McKesson Corporation (NYSE: MCK) shares have faced recent downward pressure driven by a combination of macro market headwinds, cybersecurity concerns, and pricing shifts in the healthcare sector:

  • Global Bond-Market Rout: Rising Treasury yields (surging past 5%) and broader macro market pressure have hit rate-sensitive healthcare and distribution stocks.
  • Third-Party Cybersecurity Incident: Investors have reacted to a disclosed cybersecurity incident impacting third-party applications and data exfiltration within McKesson’s Oncology-related business.
  • GLP-1 Pricing Pressure: Rapid changes and declining cash-pay prices for GLP-1 weight-loss drugs have shifted prescriptions away from traditional insurance models, creating mild headwinds in segments like Prescription Technology Solutions.
  • Macro & Valuation Overhangs: The pullback follows earlier valuation adjustments, lowered analyst price targets (such as BofA adjusting targets), and broader caution ahead of upcoming corporate earnings.

Is McKesson a good buy right now?

McKesson (NYSE: MCK) is generally viewed as a Moderate Buy by Wall Street analysts, trading around $902 following a recent stock bump.

Key Factors Supporting a Buy

  • CVS Partnership Extension: McKesson recently reached an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032, providing long-term revenue stability.
  • Strong Guidance: The company reaffirmed its fiscal year 2027 adjusted earnings per share (EPS) forecast of $44.20 to $45.00 and targets a long-term annual adjusted EPS growth rate of 13% to 16%.
  • Aging Demographics: As a leading healthcare distributor, McKesson benefits directly from structural tailwinds as an aging U.S. population drives higher demand for medical products and prescriptions.
  • Analyst Price Targets: Consensus estimates from major tracking firms put the average 12-month price target near $973 to $989, representing an estimated upside of roughly 8% to 10% from current trading levels. According to Zacks Investment Research, the stock maintains a high brokerage recommendation score.

Risks and Considerations

  • Short-Term Momentum vs. Value: While value and growth metrics remain solid (with a Zacks Growth Score of A), short-term technical indicators suggest a more neutral "hold" or cautious entry point depending on your trading style.
  • Low Dividend Yield: MCK pays a relatively low dividend yield (around 0.4%), making it less ideal for pure income-focused investors.
  • Market Reliance: The company relies heavily on the U.S. market, exposing it to domestic regulatory changes and competitive pressures in drug distribution.

What is happening with McKesson?

McKesson Corporation is expanding its specialty care portfolio, managing a recent cyber incident, and extending major distribution partnerships.

Key Business Updates

  • CVS Health Extension: McKesson signed an agreement in principle to extend its major pharmaceutical distribution partnership with CVS Health through June 2032, leading the company to reaffirm its fiscal 2027 adjusted EPS guidance of $44.20 to $45.00.
  • Precision Medicine Acquisition: McKesson agreed to acquire Precision Medicine Group for roughly $2.25 billion to boost its oncology, clinical research, and drug commercialization capabilities.
  • Medical-Surgical Investment: The company closed a $1.25 billion strategic investment from Apollo Funds for a minority stake in its Medical-Surgical Solutions business, marking a step toward a potential future IPO.

Cybersecurity Incident

  • Data Breach Disclosure: McKesson confirmed a cybersecurity incident occurring between August 20 and 25, 2026, involving unauthorized access to third-party applications and data exfiltration.
  • Impact and Response: The breach affected a subset of customers within the Oncology & Multispecialty and Medical-Surgical units, exposing personal and protected health information. McKesson offered affected individuals 24-month complimentary credit monitoring and stated that systems remain operational.

Why is McKesson laying off employees?

McKesson is laying off employees and restructuring specific operations to increase operational efficiencies, reduce administrative costs, and simplify its infrastructure.

Key Reasons for Layoffs and Restructuring

  • Cost Optimization & Operational Efficiency: The company routinely outlines enterprise-wide cost programs to align its cost structure with business needs, targeting savings across divisions like Prescription Technology Solutions, Medical-Surgical Solutions, and Corporate.
  • Shifting Strategies and Tech Focus: In subsidiaries like CoverMyMeds, McKesson has reallocated resources away from legacy services toward modern technological solutions that automate complex healthcare workflows, eliminating roles that no longer match the division's direction.
  • Facility and Operations Consolidations: The company has permanently closed several distribution and fulfillment centers (such as sites in Rogers, Minnesota, Rock Hill, South Carolina, and West Seneca, New York) due to shifting market demands, lost contracts, or local infrastructure optimization.
  • Market Pressures: Divisions have faced segment-specific challenges, such as primary care market weaknesses or fluctuations in generic drug pricing that impact divisional margins.

What is going on with McKesson stock today?

McKesson Corp shares recently moved higher after the company announced an agreement in principle to extend its pharmaceutical distribution partnership with CVS Health through June 2032.

Recent Catalysts and Performance

  • CVS Health Extension: The multiyear deal extends pharmaceutical distribution across CVS retail, mail-order, and specialty pharmacies, giving investors stronger long-term revenue visibility.
  • Reaffirmed Guidance: McKesson reiterated its fiscal 2027 adjusted earnings per share (EPS) forecast of $44.20 to $45.00 and maintained its long-term annual adjusted EPS growth target of 13% to 16%.
  • Stock Price: The stock recently closed around $902.28, reflecting positive momentum following the announcement and strong foundational demand in its medical distribution network.

Del. Robinson Explains How He Wants McKesson Settlement Spent

9 related questions found

What are the 5 most undervalued stocks right now?

Based on recent market analysis and metrics from Morningstar tracking large, high-quality companies trading at significant discounts to their estimated fair value, five notably undervalued stocks include:

  • Campbell Soup Co. (CPB) – Trading at a price-to-fair-value ratio of around 0.52, offering a deep discount relative to its traditional defensive stability.
  • Yum China Holdings (YUMC) – Operating with a price-to-fair-value ratio near 0.56, presenting a steep discount backed by extensive retail footprint growth.
  • The Clorox Co. (CLX) – Sitting at roughly a 41% discount to its calculated fair value with a price-to-fair-value ratio of 0.59.
  • RELX PLC (RELX) – Trading at a price-to-fair-value ratio of 0.61, reflecting a 39% discount on robust information-based analytics cash flows.
  • Sony Group Corp. (SONY) – Positioned at a price-to-fair-value ratio of 0.69, showing an approximate 31% discount across its entertainment and tech segments.

What is the McKesson stock price prediction for 2030?

Long-term model projections for McKesson Corporation (MCK) estimate an average 2030 price target ranging from roughly $1,080 to upwards of $1,720, depending on algorithmic growth models and sustained healthcare sector performance.

Current Market Standing (2026)

  • Stock Price: Trading around the $850 – $870 range.
  • Analyst Consensus: Strong Buy consensus, with 12-month targets averaging approximately $979 to $1,002.
  • Key Growth Driver: Extended partnerships like the CVS Health distribution agreement through June 2032 continue to reinforce long-term revenue stability.

Factors Impacting 2030 Projections

  • Specialty Distribution: Growth in oncology, cell, and gene therapy distribution provides higher-margin expansion.
  • EPS Targets: Management long-term adjusted EPS growth guidance targets 13% to 16% annually.
  • Long-Range Uncertainty: Multi-year forecasts past 5 years carry high volatility and rely heavily on macro conditions and continued share repurchases.

What is the McKesson controversy?

McKesson Corporation faced major controversy for failing to report suspicious, massive orders of prescription opioids to the Drug Enforcement Administration (DEA), which contributed heavily to the U.S. opioid epidemic.

Opioid Distribution and DEA Settlements

  • 2008 Fine: McKesson paid a $13.25 million civil penalty for failing to report suspicious sales of hydrocodone to illegal internet pharmacies.
  • 2017 Record Settlement: The company paid a record $150 million civil penalty to the U.S. government for continuing to miss or ignore suspicious orders of controlled substances after its prior agreement. The case involved delayed enforcement criticized by media investigations like 60 Minutes and The Washington Post.
  • State Lawsuits: McKesson faced separate state-level legal actions, including a $37 million settlement with West Virginia regarding massive pill dumping in small communities.

Whistleblower Kickback Allegations

  • Oncology Tools: A whistleblower lawsuit accused McKesson of providing free business-management and pricing tools (like Margin Analyzer) to oncologists as illegal kickbacks.
  • Inducing Sales: The software allegedly induced doctors to purchase more expensive cancer drugs through McKesson as their primary wholesale supplier, defrauding Medicare and patients.

Who is McKesson's largest customer?

McKesson's largest customer is CVS Health Corp., which accounts for approximately 24% of the company's total consolidated revenues.

Customer Concentration Details

  • Revenue Share: Sales to CVS Health represent nearly a quarter of McKesson's overall annual revenue.
  • Top Customers: The top 10 customers and group purchasing organizations (GPOs) combined account for a substantial majority of total revenue.
  • Key Relationship: The long-term distribution agreement primarily supplies products to CVS retail, mail-order, and specialty pharmacies.

Is McKesson having issues?

McKesson's primary network and services are operating normally, though specific login sub-domains like iam.connect.mckesson.com have reported localized outages.

Current Status Overview

  • Main Services: General operations and McKesson Corporation portals are mostly online and reporting normal status.
  • Portal Status: While general main pages and Connect.mckesson.com are up, specific authentication pages such as iam.connect.mckesson.com have flagged recent connection drops.